Virtual Meetings 2021

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Sarah B Goldberg, MD, MPH
Associate Professor of Medicine
Medical Oncology, Yale School of Medicine
New Haven, Connecticut

Stephen V Liu, MD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC



Additional faculty to be announced.

SERIES MODERATOR
Neil Love, MD
Research To Practice

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for lung cancer. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Current and Emerging Role of Immune Checkpoint Inhibitors for Patients with Non-Metastatic Non-Small Cell Lung Cancer (NSCLC)

    MODULE 2: Optimal Incorporation of Immune Checkpoint Inhibitors into the Management of Patients with Metastatic NSCLC without a Targetable Mutation

    MODULE 3: Novel Immunotherapeutic Strategies Under Investigation in NSCLC

    MODULE 4: Role of Immunotherapy in Small Cell Lung Cancer (SCLC) and Malignant Pleural Mesothelioma (MPM)

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives

  • Analyze the biologic basis for the investigation of immune checkpoint inhibitors in patients with non-metastatic non-small cell lung cancer (NSCLC) and evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy.
  • Appreciate emerging Phase III findings with the use of an anti-PD-L1 antibody following the completion of chemotherapy and surgery for patients with resectable NSCLC, and consider the potential effect of this information on current and future clinical practice.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be safely integrated into routine clinical practice.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or other immunotherapy for metastatic NSCLC and consider the clinical and biologic factors impacting the recommendation of one approach versus the others.
  • Evaluate the FDA approvals of anti-PD-L1 antibodies in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these approaches can be appropriately and safely integrated into clinical practice.
  • Review the scientific justification for the investigation of immune checkpoint inhibitors in patients with malignant pleural mesothelioma (MPM) and evaluate their current clinical role as first-line therapy for individuals with unresectable disease.
  • Recall the designs of ongoing clinical trials evaluating novel anti-PD-1/PD-L1 antibody-based approaches for patients with NSCLC, SCLC and MPM and counsel appropriate patients about availability and participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr GoldbergAdvisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc. Dr LiuAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Consulting Agreements: BeiGene Ltd, Blueprint Medicines, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Turning Point Therapeutics Inc; Contracted Research: Alkermes, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Elevation Oncology, Genentech, a member of the Roche Group, Lilly, Merck, Merus BV, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel Therapeutics.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Eisai Inc, Genentech, a member of the Roche Group, and Regeneron Pharmaceuticals Inc and Sanofi Genzyme.